VivoSim prices $4 million public offering at $1.14 per share

VivoSim Labs Inc. (NASDAQ: VIVS) announced the pricing of a $4 million public offering with an initial closing of $3 million scheduled for April 1, 2026, and a second closing of $1 million planned for 30 days later, subject to certain conditions.

The initial closing consists of $3 million in common stock or pre-funded warrants at $1.14 per share and $1.139 per pre-funded warrant, representing 286,557 common shares and 2,345,022 pre-funded warrants. The company will also issue 3,947,369 common warrants to purchase up to 150% of the aggregate shares sold at the initial closing.

The common warrants carry an exercise price of $1.71 per share, are immediately exercisable, and expire five years from issuance. Pre-funded warrants have an exercise price of $0.001 per share, are immediately exercisable, and expire when fully exercised.

The second closing requires satisfaction of conditions including minimum closing price and average trading volume requirements. A New York-based single family office leads the offering subscription.

Joseph Gunnar & Co. serves as the exclusive placement agent for the offering. The securities are being offered under an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, which was declared effective on March 31, 2026.

VivoSim operates as a pharmaceutical and biotechnology services company providing drug testing using three-dimensional human tissue models of liver and intestine. The San Diego-based company offers toxicology insights through new approach methodologies that serve as alternatives to animal testing.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• Hyperscale Data ends Bitcoin mining to prep Michigan AI data center
• Intelligent Bio Solutions raises $5M in private placement